187,030 Shares in GoodRx Holdings, Inc. (NASDAQ:GDRX) Purchased by Balyasny Asset Management L.P.

Balyasny Asset Management L.P. purchased a new position in GoodRx Holdings, Inc. (NASDAQ:GDRX) during the 4th quarter, Holdings Channel reports. The fund purchased 187,030 shares of the company’s stock, valued at approximately $870,000.

Other institutional investors also recently added to or reduced their stakes in the company. National Bank of Canada FI grew its holdings in GoodRx by 34.9% during the 4th quarter. National Bank of Canada FI now owns 8,308 shares of the company’s stock worth $39,000 after acquiring an additional 2,151 shares in the last quarter. RPO LLC bought a new position in GoodRx during the 4th quarter worth about $52,000. Versor Investments LP bought a new position in GoodRx during the 4th quarter worth about $54,000. Verus Capital Partners LLC bought a new position in GoodRx during the 4th quarter worth about $55,000. Finally, Steward Partners Investment Advisory LLC bought a new position in GoodRx during the 4th quarter worth about $56,000. Hedge funds and other institutional investors own 63.77% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on GDRX. Wells Fargo & Company dropped their target price on shares of GoodRx from $8.00 to $7.00 and set an “overweight” rating on the stock in a report on Tuesday, April 29th. Truist Financial dropped their target price on shares of GoodRx from $6.50 to $5.50 and set a “hold” rating on the stock in a report on Thursday, April 10th. The Goldman Sachs Group dropped their target price on shares of GoodRx from $6.00 to $5.00 and set a “neutral” rating on the stock in a report on Friday, May 9th. Finally, UBS Group dropped their target price on shares of GoodRx from $6.00 to $5.25 and set a “neutral” rating on the stock in a report on Tuesday. Five investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $7.33.

GoodRx Stock Down 0.7%

Shares of GoodRx stock opened at $4.27 on Thursday. The firm’s 50 day moving average price is $4.47 and its 200-day moving average price is $4.71. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70. GoodRx Holdings, Inc. has a 52-week low of $3.68 and a 52-week high of $9.26. The company has a market cap of $1.64 billion, a P/E ratio of -142.33, a PEG ratio of 2.46 and a beta of 1.24.

GoodRx (NASDAQ:GDRX) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.04 by $0.05. GoodRx had a negative net margin of 2.05% and a positive return on equity of 5.35%. The firm had revenue of $202.97 million for the quarter, compared to the consensus estimate of $202.25 million. During the same quarter in the previous year, the firm earned $0.08 EPS. The company’s quarterly revenue was up 2.6% compared to the same quarter last year. On average, sell-side analysts predict that GoodRx Holdings, Inc. will post 0.13 EPS for the current fiscal year.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.